Anticorps Polyclonal de lapin anti-EGFR

EGFR Polyclonal Antibody for WB, IF/ICC, FC, IP, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, IF/ICC, FC, IP, ELISA

Conjugaison

Non conjugué

Publications(1)

N° de cat : 30139-1-AP

Synonymes

EGF R, EGF Receptor , Epidermal growth factor receptor, Proto-oncogene c-ErbB-1

---

Galerie de données de validation

• 

  WB analysis using 30139-1-AP

  A431 cells were subjected to SDS PAGE followed by western blot with 30139-1-AP (EGFR antibody) at dilution of 1:20000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of A431 using 30139-1-AP

  A431 cells were subjected to SDS PAGE followed by western blot with 30139-1-AP (EGFR antibody) at dilution of 1:18000 incubated at room temperature for 1.5 hours.

• 

  IP experiment of HeLa using 30139-1-AP

  IP result of anti-EGFR (IP:30139-1-AP, 4ug; Detection:30139-1-AP 1:4000) with HeLa cells lysate 1520 ug.

• 

  IF Staining of A431 using 30139-1-AP

  Immunofluorescent analysis of (4% PFA) fixed A431 cells using EGFR antibody (30139-1-AP) at dilution of 1:1500 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

• 

  IF Staining of HaCaT using 30139-1-AP

  Immunofluorescent analysis of (-20°C Methanol) fixed HaCaT cells using EGFR antibody (30139-1-AP) at dilution of 1:400 and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2).

• 

  FC experiment of A431 using 30139-1-AP

  1x10^6 A431 cells were surface stained with 0.25 ug EGFR Polyclonal antibody (30139-1-AP) and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2)(red), or 0.25 ug rabbit IgG isotype control (blue). Cells were not fixed.

---

Applications testées

• Résultats positifs en WB: cellules A431,
• Résultats positifs en IP: cellules HeLa,
• Résultats positifs en IF/ICC: cellules A431, cellules HaCaT
• Résultats positifs en cytométrie: cellules A431,

Dilution recommandée

• Western Blot (WB): WB : 1:5000-1:50000
• Immunoprécipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunofluorescence (IF)/ICC: IF/ICC : 1:750-1:3000
• Flow Cytometry (FC): FC : 0.25 ug per 10^6 cells in a 100 µl suspension

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• WB: See 1 publications below

Informations sur le produit

30139-1-AP cible EGFR dans les applications de WB, IF/ICC, FC, IP, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: Protéine recombinante
• Nom complet: epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)
• Masse moléculaire calculée: 134kd
• Poids moléculaire observé: 145-165 kDa
• Numéro d’acquisition GenBank: NM_005228.5
• Symbole du gène: EGFR
• Identification du gène (NCBI): 1956
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

EGFR is a receptor for EGF, but also for other members of the EGF family, as TGF-alpha, amphiregulin, betacellulin, heparin-binding EGF-like growth factor, GP30 and vaccinia virus growth factor. ERBB1 is involved in the control of cell growth and differentiation. Phosphorylates MUC1 in breast cancer cells and increases the interaction of MUC1 with C-SRC and CTNNB1/beta-catenin. Isoform 2/truncated isoform of ERBB1 may act as an antagonist. EGFR is associated with lung cancer.

Publications

Species	Application	Title
human	WB	Cytojournal; Investigating the anti-cancer potential of sulfatase 1 and its underlying mechanism in non-small cell lung cancer; Authors - Bingling Zhang

{{ptg:RelatedPrimaryAntibodies}}